John C. McCormick
Managing Director @ InnovaHealth Partners
New York, United States
John C. McCormick is a Series B investor at InnovaHealth Partners in New York focused on Medical and Biotechnology. Mr. McCormick's is the Managing Director at InnovaHealth Partners, LP. He attended MIT Sloan School of Management.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries John C. McCormick invests in
Stages John C. McCormick invests in
Countries John C. McCormick invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 1 (20%)
- Biotechnology 1 (20%)
- Manufacturing 1 (20%)
- Developer Platform 1 (20%)
Stage
- Series B 1 (20%)
- Series C 1 (20%)
- Private Equity 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
OrthoAccel Technologies
|
OrthoAccel Technologies (OATI) designs, develops, markets, and sells the most revolutionary device in orthodontics – the Celerect 1000 – that cuts treatment time for braces in half and works in combination with all existing orthodontic bracket technologies. This proprietary technology (three issued patents) is licensed from the University ofIllinois at Chicago and the company has engaged the leading researchers in this field including the inventor, Dr. Jeremy Mao, at Columbia University, Baylor College of Dentistry, and the University of Texas Health Sciences Center, Dental Branch. Together with these world-class partners, management will commercialize this innovation by 2009. | $15M / Series C / Jan 12, 2017 | |
|
OrthoAccel Technologies
|
OrthoAccel Technologies (OATI) designs, develops, markets, and sells the most revolutionary device in orthodontics – the Celerect 1000 – that cuts treatment time for braces in half and works in combination with all existing orthodontic bracket technologies. This proprietary technology (three issued patents) is licensed from the University ofIllinois at Chicago and the company has engaged the leading researchers in this field including the inventor, Dr. Jeremy Mao, at Columbia University, Baylor College of Dentistry, and the University of Texas Health Sciences Center, Dental Branch. Together with these world-class partners, management will commercialize this innovation by 2009. | $12M / Series C / May 04, 2016 | |
|
OrthoAccel Technologies
|
OrthoAccel Technologies (OATI) designs, develops, markets, and sells the most revolutionary device in orthodontics – the Celerect 1000 – that cuts treatment time for braces in half and works in combination with all existing orthodontic bracket technologies. This proprietary technology (three issued patents) is licensed from the University ofIllinois at Chicago and the company has engaged the leading researchers in this field including the inventor, Dr. Jeremy Mao, at Columbia University, Baylor College of Dentistry, and the University of Texas Health Sciences Center, Dental Branch. Together with these world-class partners, management will commercialize this innovation by 2009. | $5M / Series B / Jan 23, 2014 | |
|
OrthoAccel Technologies
|
OrthoAccel Technologies (OATI) designs, develops, markets, and sells the most revolutionary device in orthodontics – the Celerect 1000 – that cuts treatment time for braces in half and works in combination with all existing orthodontic bracket technologies. This proprietary technology (three issued patents) is licensed from the University ofIllinois at Chicago and the company has engaged the leading researchers in this field including the inventor, Dr. Jeremy Mao, at Columbia University, Baylor College of Dentistry, and the University of Texas Health Sciences Center, Dental Branch. Together with these world-class partners, management will commercialize this innovation by 2009. | $12.5M / Series B / May 29, 2013 | |
|
OrthoAccel Technologies
|
OrthoAccel Technologies (OATI) designs, develops, markets, and sells the most revolutionary device in orthodontics – the Celerect 1000 – that cuts treatment time for braces in half and works in combination with all existing orthodontic bracket technologies. This proprietary technology (three issued patents) is licensed from the University ofIllinois at Chicago and the company has engaged the leading researchers in this field including the inventor, Dr. Jeremy Mao, at Columbia University, Baylor College of Dentistry, and the University of Texas Health Sciences Center, Dental Branch. Together with these world-class partners, management will commercialize this innovation by 2009. | Private Equity / Apr 30, 2012 |
Co-Investors
About InnovaHealth Partners
InnovaHealth Partners is an investment firm concentrating on growth buyouts of late stage medical technology companies.
InnovaHealth Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ariella Golomb
Partner & Founder
|
|||
|
John C. McCormick
Managing Director
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does John C. McCormick invest in?
John C. McCormick invests primarily in Medical, Biotechnology and Manufacturing startups, most often at Series B and Series C stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact John C. McCormick?
Public channels for John C. McCormick include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did John C. McCormick last invest?
The most recent investment recorded for John C. McCormick closed in Jan 2017. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
